Last updated: July 28, 2026
CLINIMIX 8/14 Sulfite Free in Dextrose 14% Plastic Container Suppliers: Who Manufactures and Supplies the Product for US Distribution?
CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER is supplied through a US distribution chain that typically includes: (1) the marketing authorization holder in the US, (2) contract manufacturers that produce the sterile parenteral nutrition (PN) admixture containers, and (3) wholesale distributors that place inventory with hospitals, long-term care facilities, and group purchasing organizations (GPOs). Exact supplier identity depends on the National Drug Code (NDC) and container configuration.
Who supplies CLINIMIX 8/14 sulfite free in dextrose 14% in plastic container in the US?
Primary US supply chain pattern for PN products
For PN admixtures in plastic containers, the “supplier” you see in procurement systems can be one of three roles:
- NDA holder / marketing authorization holder listed on the FDA label and packaging.
- Manufacturer of record listed on FDA labeling/registration and the product’s NDC labeler.
- Wholesaler/GPO distributor listed in purchasing catalogs (often not the manufacturer).
To identify the true upstream supplier you have to map the procurement listing (NDC/labeler) to:
- the FDA labeler/manufacturer of record for that specific NDC, and
- the sterile injectable manufacturing site(s) registered for the finished dosage form.
Commercial buying reality
Hospitals and home-infusion providers commonly source CLINIMIX through:
- national wholesalers (carrying the NDC),
- GPO contracts (which control which distributor ships the product),
- specialty distribution channels for PN compounding workflows.
Because your request is for “suppliers” without an NDC, the listing-to-supplier mapping cannot be made deterministically.
Which companies manufacture CLINIMIX 8/14 sulfite free dextrose 14% plastic container?
Key manufacturing constraint for this dosage form
CLINIMIX is a sterile, nutrition parenteral solution in multilayer plastic containers. That manufacturing process requires:
- container filling under aseptic conditions,
- nitrogen blanketing or controlled oxygen conditions depending on sulfite-free stability strategy,
- and downstream QA release for PN admixture products.
In practice, the manufacturer of record can be different from the marketing brand owner if the brand uses contract sterile manufacturing.
How to identify the manufacturer of record (what matters)
For each CLINIMIX 8/14 sulfite-free presentation, the only defensible “manufacturer” attribution comes from:
- the FDA “labeler” and “manufacturer” fields tied to the NDC, and
- the company listed on the US package label for that NDC.
Without the NDC, multiple presentations and strengths across CLINIMIX SKUs can share similar names but different labelers.
What wholesalers and GPO distributors carry CLINIMIX 8/14 sulfite free dextrose 14% plastic container?
Common distributor categories
Even when the upstream manufacturer is fixed, the “supplier” in procurement is often:
- a national wholesaler (ship-to hospitals),
- a specialty distributor for nutrition/infusion products,
- or a GPO contracting distributor.
Procurement catalog logic
Procurement systems are typically keyed on:
- NDC,
- package size,
- and “contract price” under a specific GPO.
So the distributor that “supplies” the product depends on the exact NDC and contract.
Are there multiple CLINIMIX 8/14 sulfite free dextrose 14% plastic container versions with different labelers?
Yes, SKUs split by NDC
CLINIMIX includes multiple strengths, electrolytes, and ingredient qualifiers (including sulfite-free variants). Each variant can have:
- a distinct NDC,
- different labeler/manufacturer-of-record,
- and different storage/shipping classifications.
That means “suppliers” can change across variants even if the clinical name is close.
How does supplier selection affect tender bids and hospital contracting for CLINIMIX?
Cost and availability drivers
Supplier risk is driven by:
- NDC-specific inventory allocation,
- container supply continuity (plastic container supply and sterile filling capacity),
- and contract lane coverage (GPO pricing and shipper assignment).
Litigation and substitution risk
If competing PN solutions exist on contract, the ability to substitute can affect who is considered a “supplier” in downstream purchasing. That is NDC- and contract-specific.
Key takeaways
- “Supplier” for CLINIMIX 8/14 sulfite free in dextrose 14% plastic container is NDC-dependent. The manufacturer of record and the distributor that ships the product can differ.
- The only reliable way to name upstream suppliers is to map the exact NDC presentation to the FDA labeler/manufacturer fields and then to GPO/wholesale catalog listings.
- Without the NDC, the supplier list cannot be stated accurately.
FAQs
-
How do I identify the manufacturer of CLINIMIX 8/14 sulfite free dextrose 14% plastic container?
Use the NDC labeler/manufacturer fields on the FDA listing for the exact NDC.
-
Does the sulfite-free qualifier change the supplier/manufacturer for CLINIMIX?
It can, because it often corresponds to different NDCs and sometimes different labelers.
-
Which hospitals typically source CLINIMIX from distributors vs contract manufacturers?
Hospitals buy through distributors under GPO contract terms, while contract manufacturers supply the finished product upstream.
-
Can CLINIMIX be substituted with another PN solution without affecting stability/safety?
Substitution depends on exact composition, container compatibility, and NDC-level label content.
-
What documentation is needed to confirm a supplier for CLINIMIX in procurement?
The exact NDC, labeler/manufacturer-of-record from FDA labeling, and the distributor shipping catalog entry.
References
- FDA. Drug Listing Data (NDC Directory / SPL labeler and product information). U.S. Food and Drug Administration.
- FDA. National Drug Code Directory. U.S. Food and Drug Administration.
